<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37487609</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy.</ArticleTitle><Pagination><StartPage>1328</StartPage><EndPage>1340</EndPage><MedlinePgn>1328-1340</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/ard-2023-224242</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been revealed by large cardiovascular outcome trials among patients with type 2 diabetes. However, the effect of SGLT2 inhibitors on lupus nephritis (LN) and its underlying mechanisms remain unknown.</AbstractText><AbstractText Label="METHODS">We applied empagliflozin treatment to lupus-prone MRL/<i>lpr</i> mice to explore the renal protective potential of SGLT2 inhibitors. An SGLT2 knockout monoclonal podocyte cell line was generated using the CRISPR/Cas9 system to examine the cellular and molecular mechanisms.</AbstractText><AbstractText Label="RESULTS">In MRL/<i>lpr</i> mice treated with empagliflozin, the levels of mouse anti-dsDNA IgG-specific antibodies, serum creatinine and proteinuria were markedly decreased. For renal pathology assessment, both the glomerular and tubulointerstitial damages were lessened by administration of empagliflozin. The levels of SGLT2 expression were increased and colocalised with decreased synaptopodin in the renal biopsy samples from patients with LN and MRL/<i>lpr</i> mice with nephritis. The SGLT2 inhibitor empagliflozin could alleviated podocyte injury by attenuating inflammation and enhanced autophagy by reducing mTORC1 activity. Nine patients with LN treated with SGLT2 inhibitors with more than 2 months of follow-up showed that the use of SGLT2 inhibitors was associated with a significant decrease in proteinuria from 29.6% to 96.3%. Moreover, the estimated glomerular filtration rate (eGFR) was relatively stable during the treatment with SGLT2 inhibitors.</AbstractText><AbstractText Label="CONCLUSION">This study confirmed the renoprotective effect of SGLT2 inhibitors in lupus mice, providing more evidence for non-immunosuppressive therapies to improve renal function in classic autoimmune kidney diseases such as LN.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Xin-Yu</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Shuang-Shuang</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education of China, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>He</LastName><ForeName>Ying-Xin</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education of China, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Li-Jie</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education of China, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Fu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Qi-Meng</ForeName><Initials>QM</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Yu-Hui</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education of China, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Li-Pei</ForeName><Initials>LP</Initials><Identifier Source="ORCID">0000-0001-9977-9744</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hong-de</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education of China, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yong-Chun</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education of China, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Yuan-Yuan</ForeName><Initials>YY</Initials><Identifier Source="ORCID">0000-0002-5872-3311</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China qqyyiillyy@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>HDC1R2M35U</RegistryNumber><NameOfSubstance UI="C570240">empagliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051297">Sodium-Glucose Transporter 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050199" MajorTopicYN="Y">Podocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051297" MajorTopicYN="N">Sodium-Glucose Transporter 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Lupus Nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37487609</ArticleId><ArticleId IdType="doi">10.1136/ard-2023-224242</ArticleId><ArticleId IdType="pii">ard-2023-224242</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>